US · Healthcare · Medical Devices
EPS came in at 0.78 against a street estimate of 0.73 — a beat of 6.8%.
Analysts rate Edwards Lifesciences Corp a buy (14 buy, 17 hold, 1 sell out of 32) with an average price target of $100.96.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.13% |
| Vanguard Capital Management, LLC | 6.55% |
| Vanguard Portfolio Management, LLC | 4.59% |
| State Street Corp | 4.57% |
| Wellington Management Company LLP | 3.82% |
| JPMorgan Chase & Co | 3.78% |
| Bank of New York Mellon Corp | 2.91% |
| FMR Inc | 2.52% |
| Document | Date |
|---|---|
| Results announced · Q3 2026 | 2026-07-23 |
| Board / officer change · Q2 2026 | 2026-05-08 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Board / officer change · Q2 2026 | 2026-05-04 |
| Results announced · Q2 2026 | 2026-04-23 |
| Proxy statement · Q2 2026 | 2026-03-26 |
| Annual report FY2025 | 2026-02-25 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Accelerated share repurchase agreement entered into Edwards Lifesciences Corporation announced on August 19, 2025, that it has entered into an accelerated share repurchase (ASR) agreement. An ASR is a financial arrangement where a company buy | 2025-08-19 |
| FTC moves to block proposed acquisition of JenaValve Technology Edwards Lifesciences announced on August 6, 2025, that the U.S. Federal Trade Commission (FTC) has moved to block the company's acquisition of JenaValve Technology, Inc. This is a regulatory | 2025-08-06 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Edwards Lifesciences Corp — free to start.
Google PlayApp StoreData updated 2026-08-05.